163 related articles for article (PubMed ID: 20223922)
1. Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.
Giuriato S; Foisseau M; Dejean E; Felsher DW; Al Saati T; Demur C; Ragab A; Kruczynski A; Schiff C; Delsol G; Meggetto F
Blood; 2010 May; 115(20):4061-70. PubMed ID: 20223922
[TBL] [Abstract][Full Text] [Related]
2. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation.
Lamant L; Dastugue N; Pulford K; Delsol G; Mariamé B
Blood; 1999 May; 93(9):3088-95. PubMed ID: 10216106
[TBL] [Abstract][Full Text] [Related]
3. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
[TBL] [Abstract][Full Text] [Related]
4. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas.
Drexler HG; Gignac SM; von Wasielewski R; Werner M; Dirks WG
Leukemia; 2000 Sep; 14(9):1533-59. PubMed ID: 10994999
[TBL] [Abstract][Full Text] [Related]
5. Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy.
Giuriato S; Faumont N; Bousquet E; Foisseau M; Bibonne A; Moreau M; Al Saati T; Felsher DW; Delsol G; Meggetto F
Cancer Biol Ther; 2007 Aug; 6(8):1318-23. PubMed ID: 17660712
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas.
Dejean E; Renalier MH; Foisseau M; Agirre X; Joseph N; de Paiva GR; Al Saati T; Soulier J; Desjobert C; Lamant L; Prósper F; Felsher DW; Cavaillé J; Prats H; Delsol G; Giuriato S; Meggetto F
Leukemia; 2011 Dec; 25(12):1882-90. PubMed ID: 21778999
[TBL] [Abstract][Full Text] [Related]
7. Involvement of oncogenic tyrosine kinase NPM-ALK in trifluoperazine-induced cell cycle arrest and apoptosis in ALK
Hu L; Zhang X; Wang J; Wang S; Amin HM; Shi P
Hematology; 2018 Jun; 23(5):284-290. PubMed ID: 29086626
[TBL] [Abstract][Full Text] [Related]
8. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases.
Onciu M; Behm FG; Downing JR; Shurtleff SA; Raimondi SC; Ma Z; Morris SW; Kennedy W; Jones SC; Sandlund JT
Blood; 2003 Oct; 102(7):2642-4. PubMed ID: 12816858
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice.
Merz H; Kaehler C; Hoefig KP; Branke B; Uckert W; Nadrowitz R; Cerny-Reiterer S; Herrmann H; Feller AC; Valent P
Oncotarget; 2010 Jun; 1(2):104-119. PubMed ID: 21297223
[TBL] [Abstract][Full Text] [Related]
10. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity.
Cussac D; Greenland C; Roche S; Bai RY; Duyster J; Morris SW; Delsol G; Allouche M; Payrastre B
Blood; 2004 Feb; 103(4):1464-71. PubMed ID: 14563642
[TBL] [Abstract][Full Text] [Related]
11. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R
Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060
[TBL] [Abstract][Full Text] [Related]
12. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.
Chiarle R; Gong JZ; Guasparri I; Pesci A; Cai J; Liu J; Simmons WJ; Dhall G; Howes J; Piva R; Inghirami G
Blood; 2003 Mar; 101(5):1919-27. PubMed ID: 12424201
[TBL] [Abstract][Full Text] [Related]
13. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
Werner MT; Zhao C; Zhang Q; Wasik MA
Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of NPM-ALK fusion transcript overexpression in ALK-positive anaplastic large-cell lymphoma.
Li C; Takino H; Eimoto T; Ishida T; Inagaki A; Ueda R; Suzuki R; Yoshino T; Nakagawa A; Nakamura S; Inagaki H
Mod Pathol; 2007 Jun; 20(6):648-55. PubMed ID: 17464320
[TBL] [Abstract][Full Text] [Related]
15. TrkA is a binding partner of NPM-ALK that promotes the survival of ALK
Shi W; George SK; George B; Curry CV; Murzabdillaeva A; Alkan S; Amin HM
Mol Oncol; 2017 Sep; 11(9):1189-1207. PubMed ID: 28557340
[TBL] [Abstract][Full Text] [Related]
16. Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo.
Coluccia AM; Perego S; Cleris L; Gunby RH; Passoni L; Marchesi E; Formelli F; Gambacorti-Passerini C
Blood; 2004 Apr; 103(7):2787-94. PubMed ID: 14656879
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells.
Wan W; Albom MS; Lu L; Quail MR; Becknell NC; Weinberg LR; Reddy DR; Holskin BP; Angeles TS; Underiner TL; Meyer SL; Hudkins RL; Dorsey BD; Ator MA; Ruggeri BA; Cheng M
Blood; 2006 Feb; 107(4):1617-23. PubMed ID: 16254137
[TBL] [Abstract][Full Text] [Related]
18. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.
Laimer D; Dolznig H; Kollmann K; Vesely PW; Schlederer M; Merkel O; Schiefer AI; Hassler MR; Heider S; Amenitsch L; Thallinger C; Staber PB; Simonitsch-Klupp I; Artaker M; Lagger S; Turner SD; Pileri S; Piccaluga PP; Valent P; Messana K; Landra I; Weichhart T; Knapp S; Shehata M; Todaro M; Sexl V; Höfler G; Piva R; Medico E; Ruggeri BA; Cheng M; Eferl R; Egger G; Penninger JM; Jaeger U; Moriggl R; Inghirami G; Kenner L
Nat Med; 2012 Nov; 18(11):1699-704. PubMed ID: 23064464
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of a nuclear interacting partner of anaplastic lymphoma kinase (NIPA).
Ouyang T; Bai RY; Bassermann F; von Klitzing C; Klumpen S; Miething C; Morris SW; Peschel C; Duyster J
J Biol Chem; 2003 Aug; 278(32):30028-36. PubMed ID: 12748172
[TBL] [Abstract][Full Text] [Related]
20. β-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Anand M; Lai R; Gelebart P
Haematologica; 2011 Feb; 96(2):253-61. PubMed ID: 20971814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
